CSL LTD SP/ADR (CSLLY)
CSLLY moved a median of +0.05% 30 minutes after news, and -0.09% by the close. How CSLLY actually reacts to news — the realized, point-in-time move the market made, measured across 64 labeled events over the last three years with zero look-ahead.
CSLLY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 23% | 61 |
| 30-min | +0.05% | 56% | 64 |
| 60-min | +0.08% | 52% | 64 |
| to close | -0.09% | 47% | 64 |
| Middle 50% of CSLLY reactions | -0.41% to +0.48% |
|---|---|
| Median reaction (30-min) | +0.05% |
| Measured reactions | 64 |
Half of all CSL LTD SP/ADR news events land between -0.41% and +0.48% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CSLLY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CSLLY's baseline. Nothing else.
Recent CSLLY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases | Press release | Canada Newswire | -0.03% | +0.55% | |
| CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign | Press release | PR Newswire | +0.10% | +0.35% | |
| Public Access to ANDEMBRY® (garadacimab) Expands Across Canada for the Prevention of Hereditary Angioedema (HAE) Attacks | Press release | Canada Newswire | +0.00% | +0.56% | |
| UK Government Strengthens Vaccine Partnership with CSL Seqirus, Introducing World-First Flu vaccine (aTIVc) and Extending Health Security Pandemic Agreement | Press release | PR Newswire | +0.00% | +0.56% | |
| Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults | Press release | PR Newswire | -1.38% | -0.30% | |
| CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE) | Press release | PR Newswire | -0.64% | -0.20% | |
| CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union | Press release | Canada Newswire | -0.28% | +0.55% | |
| CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada | Press release | Canada Newswire | +0.00% | +2.06% | |
| CSL announces expansion of Illinois plasma therapy manufacturing facility | Press release | PR Newswire | -0.01% | +3.17% | |
| Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract | Press release | Canada Newswire | +0.40% | +0.00% | |
| Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years | Press release | PR Newswire | -0.15% | -0.66% | |
| CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) | Press release | PR Newswire | -1.25% | -1.58% | |
| Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines | Press release | PR Newswire | -0.12% | -0.05% | |
| CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B | Press release | Canada Newswire | +2.33% | +2.18% | |
| VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment | Press release | Business Wire | +0.00% | +3.65% | |
| Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE) | Press release | Canada Newswire | +0.00% | -0.73% | |
| Raising a Child with Hemophilia: Sixth Edition Now Available! | Press release | PR Web | +0.00% | +0.13% | |
| U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start | Press release | PR Newswire | +0.00% | -3.15% | |
| CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) | Press release | PR Newswire | +0.00% | +0.21% | |
| European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) | Press release | PR Newswire | -0.13% | +0.90% | |
| CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE) | Press release | PR Newswire | — | -1.41% | |
| New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza | Press release | PR Newswire | +0.06% | +0.25% | |
| CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines | Press release | PR Newswire | +0.00% | +1.96% | |
| Pharmanovia Acquires Exclusive Rights to Treatment for Parkinson’s Disease | Press release | Business Wire | +0.00% | -0.71% | |
| CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza | Press release | PR Newswire | +0.00% | +0.25% | |
| CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations | Press release | PR Newswire | — | +0.60% | |
| CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak | Press release | PR Newswire | -0.17% | -0.46% | |
| Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia | Press release | Canada Newswire | +1.12% | -0.20% | |
| CSL Joins Accumulus Synergy to Drive Industry Change | Press release | GlobeNewswire | -1.23% | -0.47% | |
| Mark Cuban Foundation and CSL Bring Free AI Bootcamp to Philadelphia Teens | Press release | GlobeNewswire | +0.32% | +0.49% | |
| CSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B | Press release | Canada Newswire | +0.00% | +0.27% | |
| CSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season | Press release | PR Newswire | +0.00% | +3.43% | |
| CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe | Press release | GlobeNewswire | +0.00% | -0.30% | |
| CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza | Press release | PR Newswire | +1.31% | +1.16% | |
| Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons | Press release | PR Newswire | -0.13% | +1.25% | |
| Mark Cuban Foundation and CSL Bring AI Bootcamp to Philadelphia Teens | Press release | GlobeNewswire | -0.29% | -0.58% | |
| Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL" | Press release | PR Web | +0.00% | +0.14% | |
| At-risk Australians now have access to a cell-based flu vaccine on the National Immunisation Program | Press release | PR Web | — | +0.40% | |
| Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients | Press release | PR Newswire | +0.00% | -1.61% | |
| Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure | Press release | PR Newswire | +0.00% | -0.18% | |
| CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season | Press release | PR Newswire | +2.72% | +4.32% | |
| Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ | Press release | Canada Newswire | -0.06% | -0.87% | |
| CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) | Press release | PR Newswire | +0.00% | -1.35% | |
| Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options | Press release | PR Newswire | -0.23% | -1.05% | |
| CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe | Press release | PR Newswire | +0.00% | -1.34% | |
| CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials | Press release | PR Newswire | +1.22% | +1.46% | |
| CSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older | Press release | Canada Newswire | +2.49% | +3.18% | |
| CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance | Press release | PR Newswire | +2.83% | +1.07% | |
| Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment | Press release | Canada Newswire | +0.00% | +2.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CSLLY section they belong to.
Where else CSLLY is measured.
CSLLY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Extendicare Inc (EXE_TSE) | 65 | -0.27% | 29% |
| MERCK KGAA SPNS/ADR (MKKGY) | 65 | +0.04% | 52% |
| Spectral Medical Inc (EDT_TSE) | 63 | 0.00% | 38% |
| Infinity Pharmaceuticals, Inc. (INFI) | 63 | +3.96% | 71% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CSL LTD SP/ADR's median reaction calculated?
Every labeled CSLLY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 64 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 56% of CSLLY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CSLLY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.